Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JA78 | ISIN: SE0007074166 | Ticker-Symbol: 40M
Frankfurt
06.06.25 | 08:01
0,166 Euro
-5,57 % -0,010
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
NANEXA AB Chart 1 Jahr
5-Tage-Chart
NANEXA AB 5-Tage-Chart

Aktuelle News zur NANEXA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
23.05.Nanexa AB: All samples analyzed from the 30 mg dose group in the NEX-22 Phase I study220Nanexa announced today that all pharmacokinetic (PK) samples from the final dose group, 30 mg of the Phase I study for NEX-22, now have been analyzed. The results show increased exposure in line with...
► Artikel lesen
06.05.Nanexa AB: Nanexa publishes interim report for January-March 2025111Very interesting data from the latest study and successful share issue. Significant events during the first quarter of 2025In January, Nanexa announced that the company had decided to carry out a directed...
► Artikel lesen
05.05.Nanexa AB: Nanexa and Applied Materials terminates collaboration138Nanexa and Applied Materials, Inc. have collaborated since 2020 regarding production equipment to be used for upscaling of the PharmaShell process. The companies have now agreed to terminate the collaboration. Through...
► Artikel lesen
05.05.Nanexa AB: Analysis of the first samples from the 30 mg dose group in the NEX-22 Phase I study shows continued promising results65Nanexa announced today that the first pharmacokinetic (PK) samples from the final dose group, 30 mg, in the ongoing Phase I study for NEX-22 have been analyzed. The results show that the PK profile...
► Artikel lesen
07.04.Nanexa AB: Continued Good Tolerability of NEX-22 at 30 mg Dose of Liraglutide in the NEX-22 Study74Nanexa AB announces that initial observations in the phase I study show that the 30 mg dose of NEX-22, a depot formulation of liraglutide, has been well tolerated by patients with type 2 diabetes who...
► Artikel lesen
25.03.Nanexa AB: Nanexa doses the last patients with 30 mg liraglutide in the NEX-22-01 study458Nanexa announces that all patients have now been included in the fourth and final dose cohort in the Phase I study of NEX-22, a one-month formulation of liraglutide. NEX-22 is a new promising treatment...
► Artikel lesen
12.03.Nanexa AB: Nanexa doses first patient in the 30 mg dose group in the Phase I study with NEX-22174Nanexa AB announces today that the first patient has been dosed in the 30 mg dose group in the ongoing Phase I study with NEX-22, the company's one-month formulation of liraglutide. The ongoing Phase...
► Artikel lesen
NANEXA Aktie jetzt für 0€ handeln
19.02.Nanexa AB: Nanexa publishes year-end report and Q4 report 2024830The clinical Phase I study conducted in the NEX-22 project with good results and focus on the evaluation with Novo Nordisk has provided a good starting point for 2025. Significant events during the...
► Artikel lesen
13.02.Nanexa AB: Bulletin from Nanexa's Extraordinary General Meeting185The Extraordinary General Meeting (EGM) of Nanexa AB (publ) (the "Company") has been held on February 13, 2025, at which meeting submitted proposals were passed. The complete proposals for resolutions...
► Artikel lesen
28.01.Nanexa AB: Nanexa expands Phase I study with NEX-22 with an additional dose group232Nanexa AB announces that the phase I study with NEX-22, the company's one-month formulation of liraglutide, will resume with further dose escalation with an expected start in the first quarter of 2025....
► Artikel lesen
10 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1